Risk of stroke, TIA, MACE and major bleeding events during vitamin K-antagonist treatment stratified by renal function within the entire population.

Definitions: no-CKD  =  estimated glomerular filtration rate (eGFR) >60 ml/min, moderate CKD  =  eGFR 30–60 ml/min, severe CKD  =  eGFR <30 ml/min.
Abbreviations: CKD  =  chronic kidney disease, PY  =  patient years, CI  =  confidence interval, HR  =  hazard ratio, MACE  =  major adverse cardiovascular event, TIA  =  transient ischemic attack.
‡Reported incidences for patients with an eGFR 30–60 or eGFR >60 ml/min are influenced by sampling of patients matched for age and gender to those with an eGFR <30 ml/min.
* HR adjusted for age, gender, hypertension, the use of platelet-inhibitors, diabetes mellitus and congestive heart failure.
†HR adjusted for age and gender. Further correcting resulted in non-converging coefficients.